The aim of this translational research study was to investigate the effect of osimertinib on the changes in LB (both CTCs and ctDNA) status in patients with EGFR-mutant NSCLC and to assess the clinical relevance of those changes. Here, EGFR is linked to non-small cell lung carcinoma.